- Home
- DXLG vs NRXP Comparison
DXLG vs NRXP Comparison
Compare DXLG & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | NRXP |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 63.5M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXLG | NRXP |
|---|---|---|
| Price | $1.19 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $30.50 |
| AVG Volume (30 Days) | 223.2K | ★ 461.9K |
| Earning Date | 12-11-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $442,120,000.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $1.17 |
| 52 Week High | $3.10 | $6.01 |
Technical Indicators
Market Signals| Indicator | DXLG | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 37.62 |
| Support Level | $1.01 | $2.22 |
| Resistance Level | $1.58 | $2.39 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 35.77 | 4.26 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.